

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 2, 2018**

---

**ASSEMBLY BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-35005**  
(Commission  
File Number)

**20-8729264**  
(I.R.S. Employer  
Identification No.)

**11711 N. Meridian St., Suite 310  
Carmel, Indiana 46032**  
(Address of principal executive offices, including zip code)

**(317) 210-9311**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Compensatory Arrangements of Certain Officers.**

**(b)**

Effective as of April 2, 2018, Thomas E. Rollins, Chief Development Officer of Assembly Biosciences, Inc. (the “Company”) and a named executive officer of the Company, transitioned his duties as an executive officer, including his policy-making functions, to the Company’s newly hired Senior Vice President, Chief Scientific Officer Microbiome, Jacqueline S. Papkoff, Ph.D. Mr. Rollins will remain with the Company, and this change in his responsibilities will allow him to focus on alliance management and development.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 2, 2018

Assembly Biosciences, Inc.

By: /s/ Derek A. Small  
Derek A. Small  
President and Chief Executive Officer

---